Abstract:Metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) are rising in incidence and are an increasingly common cause of cirrhosis and hepatocellular carcinoma (HCC). The gut microbiome is closely connected to the liver via the portal vein, and has recently been identified as a predictor of liver disease state. Studies in NAFLD, cirrhosis and HCC have identified certain microbial signatures associated with these diseases, with the disease-associated microbiome changes collectively referred to as dysbiosis. The pathophysiologic underpinnings of these observations are an area of ongoing investigation, with current evidence demonstrating that the gut microbiome can influence liver disease and carcinogenesis via effects on intestinal permeability (leaky gut) and activation of the innate immune system. In the innate immune system, pathogen recognition receptors (Toll like receptors) on resident liver cells and macrophages cause liver inflammation, fibrosis, hepatocyte proliferation and reduced antitumor immunity, leading to chronic liver disease and carcinogenesis. Dysbiosis-associated changes include increase in secondary bile acids and reduced expression of FXR (nuclear receptor), which have also been associated with deleterious effects on lipid and carbohydrate metabolism associated with progressive liver disease. Longitudinal experimental and clinical studies are needed in different populations to examine these questions further. The role of therapeutics that modulate the microbiome is an emerging field with experimental studies showing the potential of diet, probiotics, fecal microbiota transplantation and prebiotics in improving liver disease in experimental models. Clinical studies are ongoing with preliminary evidence showing improvement in liver enzymes and steatosis. The microbial profile is different in responders to cancer immunotherapy including liver cancer, but whether or not manipulation of the microbiome can be utilized to affect response is being investigated.

Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review

Modulation of Gut Microbiota by Probiotics to Improve the Efficacy of Immunotherapy in Hepatocellular Carcinoma

Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view

Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response

Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics

An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease

Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Liver Transplantation

The Gut Microbiome and Hepatocellular Carcinoma: Implications for Early Diagnostic Biomarkers and Novel Therapies

Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

Current, emerging, and potential therapies for non-alcoholic steatohepatitis

Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions

The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma

Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma

Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases

MicroRNAs and Nonalcoholic Steatohepatitis: A Review

The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology

Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease

Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment